Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent co...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

RocketFlow Sep. 21 at 7:57 PM

$KALA Leading asset KPI-012 targets rare corneal diseases...

0 · Reply

MingChoo Sep. 20 at 11:48 AM

$KALA

0 · Reply

CandleSnipe Sep. 18 at 11:46 PM

$KALA decent move

0 · Reply

Ozyil Sep. 14 at 10:08 PM

$KALA i got out with small gains 🙂 might re-enter low again for another swing

0 · Reply

et1000 Sep. 11 at 11:11 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $SLS $KALA $PALI $KEEL swings

1 · Reply

focafoca99 Sep. 10 at 10:08 PM

$KALA locked in an exclusive distribution and reseller agreement with Virotek for ophthalmology genetic testing.

0 · Reply

Ozyil Sep. 10 at 10:26 AM

$KALA oversold, don't sleep on this, imo

0 · Reply

Alikhan001 Sep. 9 at 7:28 PM

$SUNE $FTFT next $KALA 🔥🔥🥩🥩

1 · Reply

MrTicker Sep. 9 at 2:16 PM

$KALA volume picking up.. could see a delayed run from previous news.. Kala Bio And Virotek Finalizes Definitive Exclusive Distribution And Reseller Agreement And Related Quality, Brand, And Data Protection Agreements BENZINGA 7:32 AM ET 9/3/2026

0 · Reply

IntiTheSunGod Sep. 9 at 2:02 PM

$KALA IMRN has $9M cash runaway to sustain company for 2yrs. Cost to borrow over 700% and 0 shares available. Recent partnership with consulting firm as they seek clinical licensing partner for FDA approved IND. company has proven product sold in Australia, Canada and USA.

0 · Reply

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Sep 11, 2026, 8:00 AM EDT - 11 days ago

KALA BIO Proxy statement: Proxy filing

2026-09-03T12:40:37.000Z - 18 days ago

Kala Bio, Virotek announce exclusive distribution and reseller agreement

Sep 3, 2026, 8:30 AM EDT - 19 days ago

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

2026-09-01T11:55:20.000Z - 21 days ago

Kala Bio, Virotek enters LOI for distribution agreement

Sep 1, 2026, 7:45 AM EDT - 21 days ago

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Aug 19, 2026, 7:00 AM EDT - 4 weeks ago

KALA BIO Quarterly report: Q2 2026

Jun 12, 2026, 8:00 AM EDT - 3 months ago

KALA BIO Registration statement: Registration filing

May 15, 2026, 7:00 AM EDT - 4 months ago

KALA BIO Quarterly report: Q1 2026

2026-05-12T17:59:22.000Z - 4 months ago

Kala Bio falls -21.7%

2026-05-07T22:27:13.000Z - 4 months ago

Kala Bio files $350M mixed securities shelf

2026-05-07T18:28:35.000Z - 4 months ago

Kala Bio announces reverse stock split

May 7, 2026, 9:00 AM EDT - 4 months ago

KALA BIO Announces Reverse Stock Split

May 7, 2026, 8:00 AM EDT - 4 months ago

KALA BIO Registration statement: Registration filing

2026-04-21T12:34:59.000Z - 5 months ago

Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine

Apr 21, 2026, 7:00 AM EDT - 5 months ago

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 15, 2026, 7:00 AM EDT - 5 months ago

KALA BIO Annual report: Q4 2025

Apr 1, 2026, 6:45 AM EDT - 5 months ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Mar 30, 2026, 8:45 AM EDT - 5 months ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

2026-03-18T13:05:59.000Z - 6 months ago

Red Light Holland engages Kala Bio with its Researgency.ai platform

Mar 18, 2026, 9:00 AM EDT - 6 months ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 6 months ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 6 months ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

2026-03-11T12:00:18.000Z - 6 months ago

KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’

PLTR

2026-03-11T10:40:33.000Z - 6 months ago

Kala Bio poised to ship first commercial AI product in about 14 days

Mar 11, 2026, 6:30 AM EDT - 6 months ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

2026-03-04T11:45:29.000Z - 6 months ago

Kala Bio announces initiative to build AI infrastructure platform

Mar 4, 2026, 6:30 AM EST - 6 months ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Feb 10, 2026, 7:00 AM EST - 7 months ago

KALA BIO Registration statement: Registration Filing

2026-02-10T11:15:48.000Z - 7 months ago

Kala Bio files to sell 241.44M shares of common stock for holders

Jan 30, 2026, 11:00 AM EST - 7 months ago

KALA BIO Transcript: AGM 2026

Jan 26, 2026, 7:00 AM EST - 7 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 8 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 5, 2026, 4:10 PM EST - 8 months ago

KALA BIO Settles Approximately $10.6 million of Debt

Dec 30, 2025, 7:00 AM EST - 8 months ago

KALA BIO Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 9 months ago

KALA BIO Proxy statement: Proxy Filing

2025-12-04T15:55:28.000Z - 9 months ago

Kala Bio announces $10M registered direct offering priced at-the-market

Dec 4, 2025, 10:45 AM EST - 9 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-12-01T12:11:04.000Z - 9 months ago

Kala Bio enters securities purchase agreement with David Lazar, names him CEO

Nov 19, 2025, 4:00 PM EST - 10 months ago

KALA BIO Quarterly report: Q3 2025

2025-09-30T13:35:26.000Z - 11 months ago

Kala Bio downgraded to Neutral from Outperform at Mizuho

2025-09-29T17:25:13.000Z - 11 months ago

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

2025-09-29T17:25:08.000Z - 11 months ago

H.C. Wainwright downgrades Kala Bio to Neutral after CHASE trial miss

2025-09-29T15:20:15.000Z - 11 months ago

Kala Bio shared no details on study miss, says Mizuho

Sep 10, 2025, 2:00 PM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 1:00 PM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Transcript: Status Update

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Slides: Status Update

Jul 9, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jun 5, 2025, 1:25 PM EDT - 1 year ago

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at Jefferies Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q1 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q4 2024

Mar 5, 2025, 11:50 AM EST - 1 year ago

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Jan 24, 2025, 7:00 AM EST - 1 year ago

KALA BIO Registration statement: Registration Filing

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Dec 4, 2024, 11:30 AM EST - 1 year ago

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Earnings release: Q3 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q2 2024

Jul 25, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Registration statement: Registration Filing

Jun 5, 2024, 12:30 PM EDT - 2 years ago

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Annual report: Q4 2023

Mar 4, 2024, 12:50 PM EST - 2 years ago

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 13, 2024, 12:00 PM EST - 2 years ago

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Earnings release: Q3 2023

Sep 5, 2023, 8:00 AM EDT - 3 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q2 2023

Aug 2, 2023, 4:01 PM EDT - 3 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 11, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Registration statement: Registration Filing

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 13, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Annual report: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Earnings release: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 1, 2023, 7:00 AM EST - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:30 AM EST - 3 years ago

KALA BIO Quarterly report: Q3 2022

Nov 8, 2022, 8:30 AM EST - 3 years ago

KALA BIO Earnings release: Q3 2022

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 9, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Sep 6, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Aug 19, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Quarterly report: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings release: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Slides: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

RocketFlow Sep. 21 at 7:57 PM

$KALA Leading asset KPI-012 targets rare corneal diseases...

0 · Reply

MingChoo Sep. 20 at 11:48 AM

$KALA

0 · Reply

CandleSnipe Sep. 18 at 11:46 PM

$KALA decent move

0 · Reply

Ozyil Sep. 14 at 10:08 PM

$KALA i got out with small gains 🙂 might re-enter low again for another swing

0 · Reply

et1000 Sep. 11 at 11:11 PM

1 · Reply

focafoca99 Sep. 10 at 10:08 PM

$KALA locked in an exclusive distribution and reseller agreement with Virotek for ophthalmology genetic testing.

0 · Reply

Ozyil Sep. 10 at 10:26 AM

$KALA oversold, don't sleep on this, imo

0 · Reply

Alikhan001 Sep. 9 at 7:28 PM

$SUNE $FTFT next $KALA 🔥🔥🥩🥩

1 · Reply

MrTicker Sep. 9 at 2:16 PM

0 · Reply

IntiTheSunGod Sep. 9 at 2:02 PM

0 · Reply

Ozyil Sep. 8 at 3:52 PM

$KALA back to 1+ dollar ?

0 · Reply

Ozyil Sep. 8 at 1:57 PM

$KALA i will stop loss if break down .48 , till then i hold. Avg .51 atm

0 · Reply

Kennyk93 Sep. 4 at 6:44 PM

$KALA bruh

0 · Reply

Ozyil Sep. 4 at 6:02 PM

$KALA bought 2k shares around .51 for swing trade. Next week doom or boom. We'll see

0 · Reply

MrAlientrader Sep. 4 at 4:50 PM

$KALA they will do another RS in the next couple weeks. No way they will get above $1 without doing RS

0 · Reply

Ozyil Sep. 3 at 8:27 PM

$KALA i missed dip buy around .50 was my plan ffs

0 · Reply

prismmarketview Sep. 3 at 3:30 PM

$KALA — exclusive U.S. distribution deal with Virotek for ophthalmology genetic testing (inherited retinal disease focus), effective Sept 4, initial 1-year exclusivity subject to commercial milestones. Capital-light structure: Kala leads sales/marketing, Virotek owns labs/logistics/reporting. Profit-sharing begins post-cost-recovery, no rev-share %, milestones, or minimums disclosed. ROFR on future Virotek ophtho products; framework to expand into oncology/preventive health later. TAM cited: $5.7B (2025) to $6.9B (2026) US genetic testing market. Financial impact not yet quantifiable. $KALA #Biotech #GeneticTesting https://prismmarketview.com/kala-bio-secures-exclusive-u-s-rights-to-viroteks-ophthalmology-genetic-testing-program/

0 · Reply

MrTicker Sep. 3 at 12:32 PM

$KALA Kala Bio And Virotek Finalizes Definitive Exclusive Distribution And Reseller Agreement And Related Quality, Brand, And Data Protection Agreements BENZINGA 7:32 AM ET 9/3/2026

0 · Reply

MrTicker Sep. 3 at 12:31 PM

$KALA Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ProgramAgreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program GLOBENEWSWIRE 7:30 AM ET 9/3/2026

0 · Reply

Stock_Catcher Sep. 3 at 12:30 PM

$KALA Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

0 · Reply

MrTicker Sep. 1 at 9:52 PM

$KALA earlier news if you missed it: Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program GLOBENEWSWIRE 6:45 AM ET 9/1/2026

0 · Reply

MrTicker Sep. 1 at 9:51 PM

$KALA on the move

0 · Reply

Market Cap	10.42M
Revenue (ttm)	0.00
Net Income (ttm)	-26.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	51,300
Avg Vol	367,920
Day's Range	N/A - N/A
Shares Out	19.34M
Stochastic %K	55%
Beta	-2.28
Analysts	Strong Buy
Price Target	$1.50